FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.

Amplification of fibroblast growth factor receptor 1 (FGFR1) occurs in approximately 10% of breast cancers and is associated with poor prognosis. However, it is uncertain whether overexpression of FGFR1 is causally linked to the poor prognosis of amplified cancers. Here, we show that FGFR1 overexpression is robustly associated with FGFR1 amplification in two independent series of breast cancers. Breast cancer cell lines with FGFR1 overexpression and amplification show enhanced ligand-dependent signaling, with increased activation of the mitogen-activated protein kinase and phosphoinositide 3-kinase-AKT signaling pathways in response to FGF2, but also show basal ligand-independent signaling, and are dependent on FGFR signaling for anchorage-independent growth. FGFR1-amplified cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1, suggesting that FGFR1 overexpression also promotes endocrine therapy resistance. FGFR1 signaling suppresses progesterone receptor (PR) expression in vitro, and likewise, amplified cancers are frequently PR negative, identifying a potential biomarker for FGFR1 activity. Furthermore, we show that amplified cancers have a high proliferative rate assessed by Ki67 staining and that FGFR1 amplification is found in 16% to 27% of luminal B-type breast cancers. Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance.

[1]  Hugo M. Horlings,et al.  Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets , 2009, Oncogene.

[2]  A. Ashworth,et al.  An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers , 2010, Breast Cancer Research and Treatment.

[3]  N. Gray,et al.  Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival (Cancer Research (2009) 69 (2244-2251)) , 2009 .

[4]  A. Ashworth,et al.  Mixed micropapillary–ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components , 2009, The Journal of pathology.

[5]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[6]  N. Gray,et al.  Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. , 2009, Cancer research.

[7]  J. Fridlyand,et al.  Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis , 2009, Oncogene.

[8]  Philippe Dessen,et al.  Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array , 2009, Clinical Cancer Research.

[9]  A. Ashworth,et al.  A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines , 2009, Breast Cancer Research and Treatment.

[10]  J. Blenis,et al.  The RSK family of kinases: emerging roles in cellular signalling , 2008, Nature Reviews Molecular Cell Biology.

[11]  Nicolas Stransky,et al.  Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. , 2008, Cancer research.

[12]  Elizabeth Iorns,et al.  A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor , 2008, The EMBO journal.

[13]  A. Ori,et al.  The heparanome and regulation of cell function: structures, functions and challenges. , 2008, Frontiers in bioscience : a journal and virtual library.

[14]  Peter Kraft,et al.  Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.

[15]  Daniel Birnbaum,et al.  Integrated profiling of basal and luminal breast cancers. , 2007, Cancer research.

[16]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[17]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Drăghici,et al.  Transforming function of the LSM1 oncogene in human breast cancers with the 8p11–12 amplicon , 2007, Oncogene.

[19]  D. Fabbro,et al.  FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. , 2006, Cancer cell.

[20]  Des Powe,et al.  FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis , 2007, Breast Cancer Research.

[21]  Judith Abrams,et al.  Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. , 2006, Cancer research.

[22]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[23]  Alan Mackay,et al.  FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas , 2006, Clinical Cancer Research.

[24]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[25]  Alan Ashworth,et al.  Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue , 2006, Modern Pathology.

[26]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[27]  F. Bertucci,et al.  Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer , 2005, Molecular Cancer Research.

[28]  Jeffrey M. Rosen,et al.  Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model , 2005, The Journal of cell biology.

[29]  Adrian V. Lee,et al.  Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  I. Ellis,et al.  A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes , 2005, Oncogene.

[31]  C. Dickson,et al.  Fibroblast growth factor signaling in tumorigenesis. , 2005, Cytokine & growth factor reviews.

[32]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[33]  J. Isola,et al.  Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization , 2004, Clinical Cancer Research.

[34]  N. Hynes,et al.  Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins , 2004, Oncogene.

[35]  Donna Albertson,et al.  Genomic and Expression Analysis of the 8p11–12 Amplicon in Human Breast Cancer Cell Lines , 2004, Cancer Research.

[36]  M. Ittmann,et al.  Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. , 2003, Cancer research.

[37]  M. Dowsett,et al.  Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation* , 2003, Journal of Biological Chemistry.

[38]  A. Rosenberg,et al.  High Basic Fibroblast Growth Factor Levels in Nipple Aspirate Fluid Are Correlated with Breast Cancer , 2002, Cancer journal.

[39]  A. Friedl,et al.  Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. , 2002, The American journal of pathology.

[40]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[41]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[42]  A. Rehemtulla,et al.  Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE , 2000, Breast Cancer Research.

[43]  C. Nguyen,et al.  Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes , 1999, Oncogene.

[44]  R. Zeillinger,et al.  Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. , 1997, Cancer research.

[45]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[46]  D. Birnbaum,et al.  Expression of the FGFR1 gene in human breast‐carcinoma cells , 1994, International journal of cancer.

[47]  A. Uchida,et al.  Serum concentrations of basic fibroblast growth factor in breast cancer. , 1994, Clinical chemistry.

[48]  P. Sismondi,et al.  FGFRI and PLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers , 1993, Genes, chromosomes & cancer.

[49]  B. Weber,et al.  Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. , 1993, Cancer research.

[50]  R. Lidereau,et al.  Point mutation at codon 12 of the Ki-ras gene in a primary breast carcinoma and the MDA-MB-134 human mammary carcinoma cell line. , 1990, Cancer letters.